Brazil recorded 910 deaths from covid-19 in the last 24 hours, between Thursday (29) and Friday (30), totaling 556,370 fatal victims of the disease in Brazil since the beginning of the pandemic. Data are from the National Council of Health Secretaries (Conass).
Regarding the number of new cases, 37,582 were confirmed in the same period, totaling 19,917,855 infected since March 2020. The moving average, calculated based on the last seven days, is 989 deaths and 35,332 cases.
São Paulo leads the ranking of cases, with 4,057,868, followed by Minas Gerais (1,966,524), Paraná (1,379.001) and Rio Grande do Sul (1,367,908). As for the number of deaths, the ranking is the same, with 138,996, 50,461, 35,233 and 33,334, respectively.
Regarding the vaccination situation in the country, only about 20% of the population has completed the vaccination schedule, that is, they have already taken the two necessary doses against covid-19, or one dose, in the case of the Janssen vaccine.
This means that 41,012,243 people completed the scheme, exactly 19.37% of the population, according to data from the press consortium on Friday (30). The first dose was applied to 100,082,100 people, representing 47.26% of the population.
What is most worrying in the Brazilian scenario is the spread of the delta variant, first identified in India. In Brazil, at least 247 cases and four deaths from the delta variant have already been registered, according to data from the Ministry of Health on Thursday (29). As the country, however, tests little, there is an underreporting of cases affected by the new strain.
Today, the dominant variant in the country is gamma, also known as P1. However, studies show that delta is up to 70% more transmissible than its predecessors, a cause for concern among experts.
In Brazil, the World Health Organization (WHO) has already warned that the strain should become dominant in the coming weeks. A study by the US Centers for Disease Control and Prevention (CDC) showed that transmission of the new strain can be more dangerous than chickenpox.
With the pace of vaccination lower than desired, there is the possibility of resistant variants to the applied vaccines, since the virus continues to circulate among the population and, therefore, has a greater capacity to generate mutations.
AstraZeneca’s vaccine, for example, has an overall effectiveness of 60% against the new variant, 15 days after the second dose is applied. Pfizer’s immunizer, 88% under the same conditions. The manufacturers of CoronaVac and Janssen still do not have enough information to generate data to prove the effectiveness against the variant.
Edition: Douglas Matos